AXT Drops On Negative Q1 2025 Profit Margins And Weak Q2 Outlook

AXT (AXTI) reported a challenging Q1 2025, with revenue down 22.7% year-over-year to $19.4 million, a negative gross margin of -$1.2 million, and a net loss of -$8.8 million, largely attributed to Chinese trade restrictions on indium phosphide exports. The company subsequently downgraded its Q2 2025 revenue outlook to $17.5-$18 million from an earlier $20-$22 million forecast, citing continued export permit delays. However, AXT's subsidiary Tongmei recently secured its initial indium phosphide export approval, leading the company to anticipate improved financial performance and positive gross margins in Q3 as export backlogs are addressed, despite the ongoing near-term headwinds.

Analysis

AXT Inc. (AXTI) is facing significant operational and financial headwinds, primarily driven by Chinese export restrictions on indium phosphide. The company's Q1 2025 results reflect this pressure, with revenue declining 22.7% year-over-year to $19.4 million, a negative gross profit of $1.2 million, and a net loss of $8.8 million. These challenges are expected to persist in the near term, as evidenced by the downgrade of Q2 2025 revenue guidance to a range of $17.5 million to $18.0 million. However, a potential inflection point is emerging, as AXT's subsidiary Tongmei recently received its first approval for indium phosphide exports. This development underpins management's expectation for a stronger Q3, where it anticipates clearing its order backlog and returning to positive gross margins. Despite the severe operational disruption, the company maintains a robust balance sheet with total assets of $333.5 million far exceeding total liabilities of $87.3 million. The stock currently trades below its book value, but its performance lags significantly behind peers like Applied Optoelectronics and CommScope, which are capitalizing on the strong underlying demand from AI, data centers, and 5G that AXT aims to serve.

Key Decisions for Investors

• Investors should closely monitor the progress of indium phosphide export shipments and management commentary on backlog clearance, as this is the primary catalyst for the anticipated Q3 financial recovery.
• Given the stock's valuation below book value but its recent poor performance, it may be prudent to await the Q2 earnings report to assess the full impact of export delays before considering a new or larger position.
• The heavy concentration of manufacturing and raw materials in China presents a significant geopolitical risk; portfolio exposure should be sized in consideration of potential future regulatory hurdles or trade restrictions.
• Note the stark performance gap between AXTI and its peers; a successful execution of its Q3 recovery plan is necessary for the company to begin closing this valuation and performance differential.